|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3970 EUR | +1.93% |
|
+6.15% | +33.22% |
| 07-01 | Nicox Submits NCX 470 New Drug Application In The United States | CI |
| 07-01 | Nicox files U.S. marketing approval application |  |
| Market Cap | 34.33M 39.23M 31.64M 29.32M 55.66M 3.72B 56.56M 379M 148M 1.84B 147M 144M 6.35B | P/E 2026 * |
-5.56x | P/E 2027 * | 39x |
|---|---|---|---|---|---|
| Enterprise Value | 34.33M 39.23M 31.64M 29.32M 55.66M 3.72B 56.56M 379M 148M 1.84B 147M 144M 6.35B | EV / Sales 2026 * |
11.4x | EV / Sales 2027 * | 3.43x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.93% | ||
| 1 week | +6.15% | ||
| Current month | +5.17% | ||
| 1 month | +7.88% | ||
| 3 months | -7.46% | ||
| 6 months | +13.43% | ||
| Current year | +33.22% |
| 1 week | 0.37 |  | 0.4 |
| 1 month | 0.34 | | 0.42 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.22 | | 0.65 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.84 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Fiscal year | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.93% | +6.15% | +77.63% | -5.48% | 39.23M | |
| +1.64% | +0.28% | +59.28% | +18.22% | 318B | |
| -1.13% | -4.56% | +28.17% | -4.33% | 70.43B | |
| +0.98% | +4.22% | +50.44% | +122.75% | 9.68B | |
| -1.29% | +3.58% | +7.01% | +2.10% | 8.78B | |
| +1.07% | -6.81% | -7.11% | +9.27% | 4.39B | |
| -5.65% | +0.56% | +11.76% | +23.41% | 4.01B | |
| +1.01% | -4.74% | -33.99% | +27.27% | 3.46B | |
| +1.48% | +3.07% | +52.43% | +61.74% | 2.78B | |
| -2.91% | -1.09% | +13.77% | -21.96% | 2.16B | |
| Average | -0.28% | -0.05% | +25.94% | +23.30% | 42.4B | |
| Weighted average by Cap. | +1.01% | -1.94% | +50.66% | +16.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.43M 2.76M 2.56M 4.86M 325M 4.94M 33.15M 12.89M 161M 12.87M 12.59M 555M | 10M 11.43M 9.22M 8.54M 16.22M 1.08B 16.48M 111M 42.97M 535M 42.9M 41.97M 1.85B |
| Net income | -6M -6.86M -5.53M -5.13M -9.73M -651M -9.89M -66.3M -25.78M -321M -25.74M -25.18M -1.11B | 1M 1.14M 922K 854K 1.62M 108M 1.65M 11.05M 4.3M 53.52M 4.29M 4.2M 185M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/26 | €0.3970 | +1.93% | 203,744 |
| 07/07/26 | €0.3895 | -1.14% | 215,134 |
| 06/07/26 | €0.3940 | +3.41% | 431,957 |
| 03/07/26 | €0.3810 | +0.40% | 122,409 |
| 02/07/26 | €0.3795 | +1.47% | 113,619 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3895EUR
Average target price
1.000EUR
Spread / Average Target
+156.74%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
